Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

September 27, 2005; 65 (6) Articles

Stroke recurrences in patients with symptomatic vs asymptomatic middle cerebral artery disease

R. Kern, W. Steinke, M. Daffertshofer, R. Prager, M. Hennerici
First published September 26, 2005, DOI: https://doi.org/10.1212/01.wnl.0000175983.76110.59
R. Kern
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Steinke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Daffertshofer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Prager
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Hennerici
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Stroke recurrences in patients with symptomatic vs asymptomatic middle cerebral artery disease
R. Kern, W. Steinke, M. Daffertshofer, R. Prager, M. Hennerici
Neurology Sep 2005, 65 (6) 859-864; DOI: 10.1212/01.wnl.0000175983.76110.59

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
947

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Background: Although the natural history of extracranial carotid artery disease has been investigated systematically, limited data are available on the course of middle cerebral artery (MCA) disease.

Methods: The authors observed 102 consecutive patients (67 men, 35 women; mean age 61.9 years) with significant MCA stenosis or occlusion as demonstrated by transcranial Doppler and transcranial color-coded duplex ultrasonography. Forty-six patients entered the study after TIA (n = 17) or stroke (n = 29); 56 patients were asymptomatic. Neurologic and ultrasound investigations were performed at regular intervals with a mean follow-up of 31 (range 6 to 117) months. Patients were continuously treated with either platelet inhibitors (n = 75) or anticoagulation (n = 27).

Results: Nineteen cerebral ischemic events (11 strokes, 8 TIAs) occurred during follow-up, resulting in an overall annual rate of 7.3%. Thirteen events (8 strokes, 5 TIAs) were attributable to the vascular territory ipsilateral to MCA disease. Patients with symptomatic MCA disease at study entry had an overall stroke risk of 12.5% per year (ipsilateral: 9.1%), whereas the annual incidence in primarily asymptomatic MCA disease was only 2.8% (ipsilateral: 1.4%; p < 0.01). Symptomatic MCA disease was an independent predictor for overall (hazard ratio [HR] 7.91, 95% CI 2.03 to 30.79; p < 0.01) and ipsilateral (HR 9.66, 95% CI 1.5 to 62.25; p = 0.02) cerebrovascular events.

Conclusions: Compared with asymptomatic middle cerebral artery disease, there was a high and continuous recurrence rate of ischemic events in symptomatic patients, which was even higher than in patients with symptomatic extracranial carotid artery disease.

Obstructive intracranial artery disease is the etiology of cerebral ischemic events in approximately 5% to 10% of white patients.1–3 In Asian acute stroke patients, it is the most common vascular lesion.4,5 Because of the wide availability of transcranial Doppler ultrasonography (TCD), transcranial color-coded duplex ultrasonography (TCCD), and magnetic resonance angiography (MRA), obstructive disease of the middle cerebral artery (MCA) and of other major intracranial brain–supplying arteries is increasingly detected in stroke patients as well as in asymptomatic individuals.6–8

In contrast to symptomatic and asymptomatic carotid artery disease, where the natural history has been illuminated in several large carotid endarterectomy trials and other prospective studies,9–14 corresponding data on intracranial vessel disease are limited. Previous studies, including the prospective extracranial-intracranial arterial bypass study, suggested an annual stroke risk in patients with symptomatic MCA disease between 4% and 15%.15–17 In asymptomatic patients, however, the risk of cerebrovascular events is unknown because most studies excluded these patients.

In contrast to retrospective studies,16,18,19 the final results of the Warfarin-Aspirin Symptomatic Intracranial Disease study (WASID) showed no advantage of anticoagulation to prevent recurrent ischemic events in patients with symptomatic intracranial arterial stenosis.20 Additionally, intracranial angioplasty has been proposed for symptomatic patients who do not respond to medical treatment.18,21 Considering the ongoing controversy on optimal therapeutic strategies for these patients, it becomes of increasing interest to determine their long-term risk of stroke recurrence.

We therefore investigated the natural history and prognosis of both symptomatic and asymptomatic MCA disease with regard to the occurrence of associated cerebral ischemia. We also sought to identify potential predictors for cerebrovascular events and to compare the efficacy of platelet inhibitors and anticoagulants for stroke prevention in these two patient groups.

Methods.

We recruited and consecutively followed symptomatic and asymptomatic patients with evidence of obstruction of one or both MCAs to assess their clinical and vascular course. Patients were included if they met the following criteria: 1) evidence of stenosis or occlusion of one or both main stems of the MCA or of one of its major branches at study entry proven by both TCD and TCCD; 2) sufficient transtemporal bone windows for consecutive bilateral insonation of the MCA; 3) attendance of at least one follow-up visit after study entry, resulting in a minimal observation period of 6 months; and 4) continuous treatment with either platelet inhibitors (acetylsalicylic acid, ticlopidine, or clopidogrel) or anticoagulants (intended international normalized ratio 2–3) according to the individual physician’s decision.

We excluded patients with other potential causes of stroke or TIA, such as ipsilateral high-grade carotid artery stenosis; cardiac sources of embolism; patients with uncertain diagnosis of MCA obstruction or inconsistent findings from TCD and TCCD; patients with intracranial stenosis due to vasculitis, vasospasm, dissection, aneurysm, basilar meningitis, or moyamoya disease; and patients who were unable or unwilling to attend the study.

One hundred ninety-two patients with sufficient temporal bone windows and obstruction of at least one of the major intracranial arteries were screened in our center within 1 year. Eighteen had an isolated obstruction in the anterior cerebral artery, 11 had an isolated obstruction in the posterior cerebral artery, 31 had an isolated obstruction in the basilar artery, and 12 had an isolated obstruction in the intracranial segment of the internal carotid artery, leaving 120 patients with stenosis or occlusion of one or both MCAs. Eleven patients were excluded: 3 patients with high-grade ipsilateral extracranial carotid artery stenosis, 4 patients with atrial fibrillation, 1 patient with a prosthetic aortic valve, 1 patient with known intracranial aneurysm, 1 patient with suspected intracranial vasculitis, and 1 patient with moyamoya disease. The remaining 109 patients were considered for inclusion, gave consent to attend neurologic and sonographic follow-up examinations, and were enrolled in the study. Four patients were lost during follow-up because they refused further participation. One patient independently stopped his treatment with platelet inhibitors. In two patients, findings of TCD and TCCD were inconsistent (MCA stenosis in TCD was not confirmed by TCCD in either case).

One hundred two patients aged 61.9 ± 13.6 years (67 men, mean age 60.7 ± 13.4 years; 35 women, mean age 64.1 ± 14 years) completed the study protocol and qualified for statistical data analysis. At study entry, patients were considered primarily symptomatic if a cerebrovascular event, including certainly diagnosed TIA or ischemic stroke, had occurred in the vascular territory of MCA disease. If there was no history of cerebrovascular events or if a TIA or a stroke occurred in a vascular territory outside the affected MCA, the patient was assigned to the asymptomatic group.

Patients were followed up for a mean period of 30.7 months (range 6 to 117 months). At the first patient visit at inclusion and at every visit during follow-up performed at regular 6- to 12-month intervals, medical history in terms of a structured interview and physical and neurologic examination, including the National Institutes of Health Stroke Scale, was obtained. The patients were routinely investigated for signs of cerebrovascular events, including TIA and stroke, risk factors, current medical treatment, side effects, and minor or major hemorrhagic complications. Risk factors included history of hypertension, diabetes, hypercholesterolemia, history of coronary heart disease, and cigarette smoking of at least 10 cigarettes per day during the past 5 years or more. All patients underwent a routine laboratory test and EKG during follow-up; a transthoracic echocardiogram was obtained in 58.9%.

Transcranial Doppler ultrasonography was performed using a 2-MHz pulse-wave probe (DWL Multi-Dop T2, DWL Elektronische Systeme GmbH, Germany) insonating the intracranial segments of the internal carotid artery, middle cerebral arteries, anterior cerebral arteries, and posterior cerebral arteries from a transtemporal approach. Intracranial parts of the vertebral artery and the basilar artery were investigated routinely by transforaminal insonation. TCCD was performed using a Philips HDI 5000 system (Philips Medical Ultrasound, The Netherlands) with a 2- to 4-MHz phased array transducer including frequency- and power-based color coding focusing on the arteries of the circle of Willis. Intracranial vessels were assessed by two experienced investigators who were unaware of each other’s findings using TCD and TCCD at study entry and at each follow-up visit. Details of transcranial ultrasound investigations and analyses are reported elsewhere.22,23 The degree of stenosis was classified according to criteria based on the peak systolic flow velocity. MCA stenosis was graded as one of three categories: low-grade (140 to 209 cm/s), moderate (210 to 280 cm/s), and high-grade (>280 cm/s). MCA occlusion was diagnosed when the Doppler signal was lacking and other ipsilateral basal cerebral arteries were identified.24

During follow-up, the diagnosis of obstructive MCA disease was confirmed by a complementary method for vascular imaging in 74% of the patients. Fifty-three percent of the patients were examined with MRA alone; 34% underwent conventional intra-arterial angiography alone; and in 13% of the patients, both MRA and conventional angiography were performed at least once during follow-up.

Middle cerebral artery disease progression or regression was recorded by TCD and TCCD data at every patient visit. Disease progression was documented if the MCA stenosis had upgraded in severity verified at two repeat visits or if stenosis progressed to occlusion. We defined disease regression as development from occlusion to stenosis, decrease of the degree of stenosis, or normalization of flow velocities confirmed at two repeat visits.

Statistical data analysis was performed with SPSS version 11.5. Univariate analysis was used to compare variables in patient groups using χ2 tests for discrete variables and t tests for contiguous variables. Ipsilateral and overall annual incidences of cerebrovascular events during the observation period were calculated. To determine independent predictors for the occurrence of ipsilateral and overall cerebrovascular events, a Cox proportional hazards model was applied that incorporated the duration of follow-up. The hazard ratio (HR) of each variable included in the model was given with 95% CI. Survival analysis was performed to compare cumulative event-free rates for the time to a cerebrovascular event between symptomatic and asymptomatic patients at study entry and between patients treated with platelet inhibitors and patients treated with oral anticoagulants. Survival curves were calculated from the Cox proportional hazards model; the difference of two survival curves was estimated by the −2 log likelihood method. For all statistical tests, p < 0.05 was considered significant.

Results.

At study entry, 56 of patients (54.9%) were classified asymptomatic; 46 of patients (45.1%) entered the study after TIA (n = 17) or stroke (n = 29) in the vascular territory ipsilateral to MCA disease. Seventy-five patients (73.5%) were continuously treated with platelet inhibitors, and 27 (26.5%) were treated with anticoagulants (table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1 Baseline characteristics of the 102 study patients and comparison of patient groups with symptomatic and asymptomatic MCA disease

Nineteen cerebrovascular events occurred during follow-up, resulting in an overall rate of 7.3% per year. Eight accidents were TIAs with complete regression of clinical symptoms within 24 hours or less, and 11 were classified as ischemic stroke. Thirteen events (8 strokes, 5 TIAs) occurred in the vascular territory ipsilateral to MCA disease (ipsilateral annual incidence 5.0%). Three patients had recurrent events: 1 patient had a stroke in the contralateral MCA territory followed by an ipsilateral event 4 months later, and 2 patients had recurrent ipsilateral TIAs. Patients with MCA occlusions exclusively had ipsilateral events (n = 3). Cerebrovascular events ipsilateral to MCA disease occurred at a mean of 16.3 months after study entry, and any cerebrovascular event occurred after 20.7 months. Statistical analysis of potential predictors for the occurrence of ipsilateral or overall cerebrovascular events is summarized in table 2 (univariate statistics) and table E-1 (available on the Neurology Web site at www.neurology.org) (Cox proportional hazards model).

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2 Potential predictors of ipsilateral and overall cerebrovascular events: Univariate analysis

Six patients died during the observation period (annual mortality 2.3%); death was classified as of vascular cause in one patient with a fatal stroke. One patient treated with anticoagulants had a major nonfatal intracerebral hemorrhage. Two other patients treated with anticoagulants experienced minor hemorrhagic complications (gingival bleeding and rectal bleeding from hemorrhoids). No hemorrhagic complications occurred during treatment with platelet inhibitors.

Doppler findings.

Middle cerebral artery obstructive disease was classified as grade I in 61 patients (59.8%), as grade II in 19 patients (18.6%), as grade III in 11 patients (10.8%), and as occlusion in another 11 patients (10.8%). Additional intracranial arterial disease was detected in 45 patients (44.1%), 29 of whom had bilateral MCA disease. Five patients had abnormalities in more than two intracranial arteries. Obstructive disease of any MCA was detected in 131 of 204 arteries. The left MCA was affected in 71 cases, and the right MCA was affected in 60 cases.

During follow-up, MCA disease was stable in 74.5% of patients, and progression was observed in 10 patients (9.8%). The degree of stenosis increased from grade I to grade II in 7 of these patients, from grade II to grade III in 2 patients, and from grade I to grade III in 1 patient. Progression from stenosis to occlusion was not observed. Regression of MCA obstruction was detected in 16 patients (15.7%). In 4 patients, MCA occlusion resolved to a stenosis (grade III and grade I each in 2 patients); the vascular course of these patients was confirmed by serial MRA. In 6 patients, the degree of stenosis decreased according to the decline of intrastenotic flow velocities, and grade I stenoses normalized in another 6 patients.

Comparison of symptomatic and asymptomatic MCA disease.

In the symptomatic group, patients were younger, patients had higher grades of MCA stenosis, and MCA occlusions were more frequent as compared with the asymptomatic group. Eighty-two percent of patients with MCA occlusion were symptomatic at study entry, compared with only 40.7% of patients with MCA stenosis. Regression of MCA obstruction was associated with symptomatic MCA disease (p = 0.04).

Symptomatic MCA disease was associated with occurrence of ipsilateral and overall cerebral ischemic events in the observation period (p < 0.01, χ2 test). Of the patients with symptomatic MCA disease, 32.6% experienced events in any vascular territory, compared with only 7.1% of the patients with asymptomatic MCA. All cerebrovascular events in asymptomatic MCA disease occurred during therapy with platelet inhibitors. In the subgroup of 13 patients with ipsilateral events, 11 had already been symptomatic at study entry. Patients with symptomatic MCA disease at study entry had an annual risk of 12.5% (ipsilateral: 9.1%), whereas the incidence in asymptomatic patients was 2.8% per year (ipsilateral: 1.4%). In the Cox proportional hazards model, symptomatic MCA disease remained an independent risk factor for recurrent TIA or stroke (HR for ipsilateral events 9.66, 95% CI 1.5 to 62.25, p = 0.02; HR for any event 7.91, 95% CI 2.03 to 30.79, p < 0.01). Cumulative event-free rates estimated in the Cox proportional hazards model (figure, A) were different between symptomatic and asymptomatic MCA disease (p = 0.03).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure. Survival curves estimated with the Cox proportional hazards model show the cumulative rate of patients remaining free of cerebrovascular events during the observation period. (A) Comparison of patients with asymptomatic MCA disease (upper curve) and with symptomatic MCA disease at study entry (lower curve; p = 0.02). (B) Comparison of patients treated with anticoagulants (upper curve) and of those treated with platelet inhibitors (lower curve; p = 0.02).

Medical treatment.

Platelet inhibitors were given more frequently for grade I MCA stenoses (p = 0.02), while anticoagulants were preferred for high-grade stenoses (p = 0.03). Most of the patients with asymptomatic MCA disease were treated with platelet inhibitors (80.4%), whereas in symptomatic MCA disease, anticoagulants were used more frequently (34.8%; p = 0.09). There was no association between demographic data, risk factors, or additional arterial disease and the choice of medical treatment.

Of the patients treated with platelet inhibitors, 22.7% experienced new events, compared with only 7.4% of those treated with anticoagulants (p = 0.08, χ2 test). In the Cox proportional hazards model, there was an association between treatment with platelet inhibitors and occurrence of cerebrovascular events in any vascular territory (HR 6.18, 95% CI 1.36 to 28.03; p = 0.02). However, no influence on the occurrence of ipsilateral cerebrovascular events was demonstrated in the univariate (p = 0.33, χ2 test) and Cox regression analyses (HR 3.96, 95% CI 0.81 to 19.46; p = 0.09). Patients treated with platelet inhibitors had an annual risk of overall cerebrovascular events of 10.3%, compared with 2.1% in patients treated with anticoagulants. Correspondingly, the survival analysis (see figure, B) shows a higher rate of cerebrovascular events in patients treated with anticoagulants (p = 0.02).

Other potential predictors of cerebrovascular events.

Age, sex, common vascular risk factors, and history of coronary heart disease had no influence on the occurrence of stroke, TIA, or vascular death. Neither disease progression nor regression showed a significant association with stroke recurrence. A higher grade of MCA obstruction was related to the occurrence of both ipsilateral (p < 0.01) and overall events (p = 0.04). In particular, among the 13 patients who experienced ipsilateral events during observation, 6 patients had a high-grade stenosis or an occlusion of the MCA. Patients with bilateral MCA disease had a higher ipsilateral (p = 0.03) and overall (p = 0.01) rate of cerebrovascular events. Additional intracranial artery disease was associated with the occurrence of cerebrovascular event in any vascular territory (p = 0.02). However, none of these variables reached significance in the Cox proportional hazards model.

Finally, a subgroup analysis after exclusion of patients with MCA occlusions was performed. It revealed similar findings regarding potential predictors of outcome events, compared with the total cohort.

Discussion.

Despite the widespread availability of valid diagnostic methods, few data on the incidence, prognosis, and treatment of intracranial arterial obstructive disease are available. Our study provides information on the differences between symptomatic and asymptomatic MCA obstructions. It demonstrates that patients with symptomatic stenoses or occlusions are a high-risk group for recurrent cerebrovascular events. Our ipsilateral recurrence rate of 9.1% per year corresponds to previous long-term observations in white patients with symptomatic MCA disease.15–18,25–27 The cumulative recurrence rate of symptomatic MCA disease seems to be even higher compared with data of symptomatic extracranial carotid artery disease28 because it continuously remains stable beyond the first year. In contrast, asymptomatic MCA disease represents a relatively benign condition with low annual incidences of TIA and stroke. The overall annual risk for TIA and stroke of 2.8% in asymptomatic patients is comparable to that of asymptomatic carotid artery disease.12,13

Intracranial arterial stenoses have been described as dynamic lesions demonstrating both progression and regression.27 In particular, progression of stenosis was identified as potential predictor of recurrent ischemic events.17 Among our population, disease progression was not associated with an increased risk of TIA and stroke. This lack of association may be due to the low incidences of TIA and stroke and the relatively small number of progressive stenoses in the current study. Another limitation of the study may be that the diagnosis of MCA obstruction was confirmed by a complementary method in only 74% and based on TCD and TCCD alone in a small minority of asymptomatic patients. Although conventional angiography is still considered the accepted standard for the detection and quantification of intracranial vessel obstruction, we relied on these noninvasive techniques because of their good sensitivity and specificity.29,30

An increasing degree of arterial obstruction can be explained by progression of an atherosclerotic lesion, whereas regressive obstructions are contrary both to current concepts of atherosclerosis and to conditions known from carotid artery disease. Although a decreasing degree of MCA obstruction was not a predictor for recurrent stroke or TIA in our study, we found a remarkably high regression rate. Furthermore, there was a significant association between regressive obstructions and symptomatic MCA disease. Lower rates of regressive stenosis have also been reported in asymptomatic compared with symptomatic MCA disease.31 This observation may be due to different pathomechanisms accounting for obstructive intracranial disease: asymptomatic stenoses of atherosclerotic nature as stable or slowly progressive condition, and symptomatic stenoses or occlusions that may be either atherosclerotic or embolic obstructions with the potential for spontaneous regression or recanalization. This hypothesis is further supported by findings that regression in symptomatic MCA disease is associated with occurrence of microembolic signals detected during the acute phase of ischemic stroke,32 whereas microembolic signals were not detected in asymptomatic or symptomatic MCA disease during the chronic phase after stroke.33

Because interventional techniques such as intracranial angioplasty and stenting develop fast as alternatives to medical treatment,21,34–36 knowledge about the natural course of intracranial obstructive disease and about the impact of conservative therapy becomes of increasing interest. However, which medical treatment should be evaluated in a randomized trial comparing conservative therapy with interventional procedures is still controversial.37 Patients with symptomatic intracranial atherosclerosis who did not respond to antithrombotic therapy were reported to be at high risk for cerebral ischemic events18 and may therefore be a target group for the medical arm of such a randomized angioplasty trial. Because of the high recurrence rate under anticoagulation in this study, one may conclude that this therapy might not be effective in intracranial artery disease. Also, in patients with previous noncardioembolic ischemic stroke, no advantage of anticoagulants for preventing stroke recurrence was demonstrated.38 Correspondingly, the final results of the WASID trial did not show a benefit of anticoagulation over aspirin to prevent recurrent ischemic events in patients with symptomatic intracranial arterial stenosis, and there was also a high rate of adverse events under treatment with anticoagulants.20

In contrast to the WASID trial, we observed low incidences of stroke and TIA in patients with MCA disease under treatment with anticoagulants, similar to previous observational studies.16,39,40 Considering our results, one may conclude that, because of the benign natural course, platelet inhibitors are preferable in asymptomatic obstructions of the MCA, whereas anticoagulants may be beneficial in selected patients with symptomatic, high-grade MCA stenoses. The different study design, inclusion of patients with stenosis of any intracranial artery, the use of higher doses of aspirin, and the shorter observation time in the WASID trial may explain this discrepancy. However, their high stroke rate of more than 17% within 2 years corresponds well with our findings in symptomatic patients.

Acknowledgment

The authors thank Joachim Brade from the Department of Medical Biostatistics in Mannheim, Germany, for help with statistics.

Footnotes

  • Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the September 27 issue to find the title link for this article.

    Disclosure: The authors report no conflicts of interest.

    Received December 1, 2004. Accepted in final form June 8, 2005.

References

  1. 1.↵
    Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995;26:14–20.
    OpenUrlAbstract/FREE Full Text
  2. 2.
    Wityk RJ, Lehman D, Klag M, et al. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996;27:1974–1980.
    OpenUrlAbstract/FREE Full Text
  3. 3.
    Caplan LR, Gorelick PB, Hier DB. Race, sex and occlusive cerebrovascular disease: a review. Stroke 1986;17:648–655.
    OpenUrlFREE Full Text
  4. 4.↵
    Wong KS, Huang YN, Gao S, et al. Intracranial stenosis in Chinese patients with acute stroke. Neurology 1998;50:812–813.
    OpenUrlAbstract/FREE Full Text
  5. 5.
    Huang YN, Gao S, Li SW, et al. Vascular lesions in Chinese patients with transient ischemic attacks. Neurology 1997;48:524–525.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Lindegaard KF, Bakke SJ, Aaslid R, Nornes H. Doppler diagnosis of intracranial artery occlusive disorders. J Neurol Neurosurg Psychiatry 1986;49:510–518.
    OpenUrlAbstract/FREE Full Text
  7. 7.
    Ley-Pozo J, Ringelstein EB. Noninvasive detection of occlusive disease of the carotid siphon and middle cerebral artery. Ann Neurol 1990;28:640–647.
    OpenUrlCrossRefPubMed
  8. 8.
    Baumgartner RW, Mattle HP, Schroth G. Assessment of >/=50% and <50% intracranial stenoses by transcranial color-coded duplex sonography. Stroke 1999;30:87–92.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991;325:445–453.
    OpenUrlCrossRefPubMed
  10. 10.
    Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415–1425.
    OpenUrlCrossRefPubMed
  11. 11.
    Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379–1387.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Hennerici M, Hulsbomer HB, Hefter H, Lammerts D, Rautenberg W. Natural history of asymptomatic extracranial arterial disease: results of a long-term prospective study. Brain 1987;110(pt 3):777–791.
    OpenUrlAbstract/FREE Full Text
  13. 13.
    Norris JW, Zhu CZ, Bornstein NM, Chambers BR. Vascular risks of asymptomatic carotid stenosis. Stroke 1991;22:1485–1490.
    OpenUrlAbstract/FREE Full Text
  14. 14.
    Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995;273:1421–1428.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. The EC/IC Bypass Study Group. N Engl J Med 1985;313:1191–1200.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Chimowitz MI, Kokkinos J, Strong J, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995;45:1488–1493.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Arenillas JF, Molina CA, Montaner J, et al. Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a long-term follow-up transcranial Doppler ultrasound study. Stroke 2001;32:2898–2904.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology 2000;55:490–497.
    OpenUrlAbstract/FREE Full Text
  19. 19.
    Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Stroke 1998;29:1389–1392.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–1316.
    OpenUrlCrossRefPubMed
  21. 21.↵
    Lee JH, Kwon SU, Lee JH, Suh DC, Kim JS. Percutaneous transluminal angioplasty for symptomatic middle cerebral artery stenosis: long-term follow-up. Cerebrovasc Dis 2003;15:90–97.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Roether J, Schwartz A, Wentz KU, Hennerici M. Middle cerebral artery stenoses: assessment by magnetic resonance angiography and transcranial Doppler ultrasound. Cerebrovasc Dis 1994;4:273–279.
  23. 23.
    Hennerici M, Neuerburg-Heusler D. Vascular diagnosis with ultrasound. Stuttgart: Georg Thieme Verlag, 1998.
  24. 24.↵
    Seidel G, Kaps M, Gerriets T. Potential and limitations of transcranial color-coded sonography in stroke patients. Stroke 1995;26:2061–2066.
    OpenUrlAbstract/FREE Full Text
  25. 25.
    Corston RN, Kendall BE, Marshall J. Prognosis in middle cerebral artery stenosis. Stroke 1984;15:237–241.
    OpenUrlAbstract/FREE Full Text
  26. 26.
    Bogousslavsky J, Barnett HJ, Fox AJ, Hachinski VC, Taylor W. Atherosclerotic disease of the middle cerebral artery. Stroke 1986;17:1112–1120.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    Akins PT, Pilgram TK, Cross III, DT Moran CJ. Natural history of stenosis from intracranial atherosclerosis by serial angiography. Stroke 1998;29:433–438.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004;363:915–924.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Rorick MB, Nichols FT, Adams RJ. Transcranial Doppler correlation with angiography in detection of intracranial stenosis. Stroke 1994;25:1931–1934.
    OpenUrlAbstract/FREE Full Text
  30. 30.
    Korogi Y, Takahashi M, Mabuchi N, et al. Intracranial vascular stenosis and occlusion: diagnostic accuracy of three-dimensional, Fourier transform, time-of-flight MR angiography. Radiology 1994;193:187–193.
    OpenUrlPubMed
  31. 31.↵
    Lorenz M, Berlit P, Diehl RR. Determinants for the prognosis of median cerebral artery processes: a retrospective analysis of 90 patients. Nervenarzt 2003;74:343–349.
    OpenUrlPubMed
  32. 32.↵
    Segura T, Serena J, Castellanos M, et al. Embolism in acute middle cerebral artery stenosis. Neurology 2001;56:497–501.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    Sliwka U, Klotzsch C, Popescu O, et al. Do chronic middle cerebral artery stenoses represent an embolic focus? A multirange transcranial Doppler study. Stroke 1997;28:1324–1327.
    OpenUrlAbstract/FREE Full Text
  34. 34.
    Marks MP, Marcellus M, Norbash AM, et al. Outcome of angioplasty for atherosclerotic intracranial stenosis. Stroke 1999;30:1065–1069.
    OpenUrlAbstract/FREE Full Text
  35. 35.
    Connors III, JJ Wojak JC. Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: evolution of technique and short-term results. J Neurosurg 1999;91:415–423.
    OpenUrlCrossRefPubMed
  36. 36.
    Marks MP, Marcellus ML, Do HM, et al. Intracranial angioplasty without stenting for symptomatic atherosclerotic stenosis: long-term follow-up. AJNR Am J Neuroradiol 2005;26:525–530.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Benesch CG, Chimowitz MI. Best treatment for intracranial arterial stenosis? 50 years of uncertainty. The WASID Investigators. Neurology 2000;55:465–466.
    OpenUrlFREE Full Text
  38. 38.↵
    Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444–1451.
    OpenUrlCrossRefPubMed
  39. 39.
    Estol CJ, Pessin MS. Anticoagulation: is there still a role in atherothrombotic stroke? Stroke 1990;21:820–824.
    OpenUrlFREE Full Text
  40. 40.
    Block F, Hoang PA. Oral anticoagulation in symptomatic intracranial stenoses. Nervenarzt 2003;74:523–526.
    OpenUrlPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Brief Communications
    Intracranial stenosis in Chinese patients with acute stroke
    K. S. Wong, Y. N. Huang, S. Gao et al.
    Neurology, March 01, 1998
  • Article
    Prevalence of stenoses and occlusions of brain-supplying arteries in young stroke patients
    Bettina von Sarnowski, Ulf Schminke, Turgut Tatlisumak et al.
    Neurology, March 06, 2013
  • Articles
    Symptomatic intracranial atherosclerosis
    Outcome of patients who fail antithrombotic therapy
    Vincent N. Thijs, Gregory W. Albers et al.
    Neurology, August 22, 2000
  • Articles
    Contrast-enhanced transcranial color-coded duplex sonography
    Efficiency and validity
    T. Gerriets, G. Seidel, I. Fiss et al.
    Neurology, April 01, 1999
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise